Owner

Untitled

Verification

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY (HRT) — COMPLETE NOTE

1. Hormone Replacement Therapy (HRT): Core Concept

HRT = Estrogen ± Progestin therapy, highly effective in:

Suppressing perimenopausal syndrome

Vasomotor instability (hot flushes, night sweats)
Psychological disturbances

Preventing estrogen-deficiency sequelae

Genital and dermal atrophy
Osteoporosis and fractures

🔑 Symptom behavior

Vasomotor symptoms → subside over a few years
Atrophic & skeletal changes → progress continuously

2. Indications & Timing (Critical Exam Rule)

HRT is restricted to limited duration for symptom control due to long-term risks.

Recommended window:

Women < 60 years, OR
Within 10 years of menopause

💡 Dose principle

Estrogen dose in HRT is much lower than contraceptive doses

3. Estrogen Therapy: Regimens & Doses

Common Estrogen Used

Conjugated estrogens

Given cyclically:

3 weeks treatment + 1 week gap

Current trend → lower doses

0.3–0.45 mg/day
(Earlier standard: 0.625 mg/day)

Estrogen Alone

✔ Used only in hysterectomised women

When progestin:

Not tolerated
Contraindicated

Low-dose estrogen alone preferred if symptoms controlled
Transdermal estradiol

Preferred by many
Certain metabolic and thrombotic advantages

4. Progestin Addition (Endometrial Protection)

Why Progestin is Added

Continuous estrogen → DUB + endometrial hyperplasia → carcinoma

Regimen

Micronized oral progesterone / MPA / norethisterone
Given for last 10–12 days of each month

Important Exam Point

Progestins:

May attenuate metabolic & cardiovascular benefits of estrogen
Main purpose → endometrial protection, not symptom relief

5. Therapeutic Effects of HRT (System-wise)

a. Menopausal Symptoms & Atrophic Changes

Vasomotor Symptoms

Respond promptly and almost completely
Primary indication for HRT

Additional Benefits

Improved:

Sleep
Body aches
Physical, mental & sexual well-being

⚠️ Mood

Estrogen alone → improves premenopausal depression
Adding progestin → may nullify this benefit

✔ Rule

Stop HRT once vasomotor symptoms abate

Genitourinary Atrophy

Estrogen arrests:

Vaginal
Vulval
Urinary atrophic changes

Relieves:

Dyspareunia
Recurrent urinary symptoms

✔ Local (vaginal) estrogen

Preferred if only local symptoms
Effective + minimal systemic risk

b. Osteoporosis & Fractures

Effects

Restores calcium balance
Prevents further bone loss
Nullifies excess fracture risk

Timing Rule

Must start before significant bone loss
Reversal of osteoporosis is minimal

Adjuncts

Calcium + Vitamin D
Weight-bearing exercise

⚠️ After stopping HRT

Accelerated bone loss restarts

Dose Evidence

Even low doses (0.3–0.45 mg/day) ↑ BMD
0.625 mg/day → more effective

Current Recommendation

❌ Estrogens no longer preferred for osteoporosis

Bisphosphonates → drugs of choice
HRT:

Not best for prevention or treatment
Not recommended >5 years
Not recommended >60 years

c. Cardiovascular Events

Estrogen Effects (Theoretical Benefits)

Improves HDL:LDL ratio
Retards atherogenesis
↓ Arterial impedance
↑ NO & prostacyclin
Prevents hyperinsulinemia

Clinical Reality

Older women with pre-existing CVD:

3× risk of VTE
↑ MI risk in first year
❌ No role in secondary prevention of CAD

🔴 Progestin Effect

Increased MI risk attributed mainly to progestin
Estrogen-alone users → no MI increase

Timing Hypothesis (Very High Yield)

HRT started within 10 years of menopause

→ ~30% reduction in MI

✔ Conclusion

Short-term HRT soon after menopause (<60 yrs) may be cardioprotective

d. Cognitive Function & Dementia (WHIMS Study)

No protection against cognitive decline
Slight global deterioration
Dementia (Alzheimer’s) incidence doubled

❌ HRT not recommended for cognitive protection

e. Cancer Risks

Breast Cancer

Estrogen stimulates growth of existing cancer
WHI:

Estrogen alone → no significant increase
Combined HRT → slightly higher risk

Medroxyprogesterone implicated

Observational Studies

California Teachers Study:

Estrogen alone → marginal increase
Estrogen + progestin → clear increase (MWS)

🔑 Key Insight

Progestin protects endometrium

BUT may increase breast cancer risk

Endometrial Cancer

Unopposed estrogen:

Endometrial hyperplasia
Irregular bleeding
Long-term carcinoma risk

✔ Standard:

Combined HRT if uterus intact

✔ Evidence:

Low-dose unopposed estrogen → no significant increase (Cochrane)
Can be used if progestin contraindicated

Colorectal Cancer

WHI showed small protective effect
Needs further confirmation

f. Other Adverse Effects

Gallstones → slightly increased risk
Migraine → may be triggered by progestins

6. Tibolone

19-norsteroid
Metabolized into 3 active metabolites:

Estrogenic
Progestogenic
Weak androgenic

Effects (2.5 mg/day)

Suppresses menopausal symptoms
↓ Gonadotropins
No endometrial stimulation
Improves:

Urogenital atrophy
Libido
Mood
Osteoporosis

Limitations

Same contraindications as HRT
Long-term risks unclear
Side effects:

Weight gain
Facial hair
Vaginal spotting

📌 Use

UVIAL 2.5 mg
One tablet daily
Start ≥12 months after menopause

7. Senile (Atrophic) Vaginitis

Prefer topical estrogen
Oral therapy rarely needed
Antibacterial may be added
Relieves:

Vaginal infection
Kraurosis vulvae

8. Other Clinical Uses of Estrogen

a. Delayed Puberty (Primary Hypogonadism)

Turner syndrome, hypopituitarism
Start cyclic estrogen at 12–13 yrs
Gradually increase dose
Add cyclic progestin later
Continue till menopausal age
GH ± low-dose androgen for height

b. Dysmenorrhea

First line → PG synthesis inhibitors
Cyclic estrogen + progestin:

Inhibits ovulation
↓ Endometrial PGs

Reserved for severe cases

c. Acne

Estrogen suppresses ovarian androgen production
Effective in girls (with progestin)
❌ Not used in boys
Topical therapy preferred

d. Dysfunctional Uterine Bleeding

Progestin cyclic therapy = treatment of choice
Estrogen → adjuvant role

e. Carcinoma Prostate

Estrogens suppress androgen production
Palliative benefit
Currently:

GnRH agonists ± anti-androgens preferred

FINAL EXAM LOCK

HRT is for symptom relief, not disease prevention
Best window: <60 years or <10 years post-menopause
Uterus present → progestin mandatory
Transdermal estrogen safer for VTE
Osteoporosis → bisphosphonates preferred
Stop HRT once vasomotor symptoms settle

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY (HRT) — MASTER TABLE (ZERO-OMISSION)

Domain	Aspect	Details (No omissions)
Definition & Purpose	What is HRT	Estrogen ± progestin therapy
	Core benefits	Suppresses vasomotor instability, psychological disturbances; prevents atrophic changes and osteoporosis
	Symptom course	Vasomotor symptoms subside over years; atrophic & skeletal changes progress continuously
Eligibility & Timing	Age window	< 60 years
	Menopause window	Within 10 years after menopause
	Duration principle	Restricted to limited duration (long-term risk)
Dose Principle	Comparison	Estrogen dose in HRT is much lower than contraceptive doses
Estrogen Therapy	Type	Conjugated estrogens
	Regimen	Cyclic: 3 weeks treatment + 1 week gap
	Current dose trend	Low dose preferred: 0.3–0.45 mg/day
	Older standard	0.625 mg/day (more effective for bone, higher risk)
Progestin Addition	Indication	Mandatory if uterus present
	Drugs	Micronized oral progesterone, medroxyprogesterone acetate, norethisterone
	Regimen	Added for last 10–12 days of each month
	Main purpose	Prevent DUB & endometrial carcinoma due to unopposed estrogen
	Limitation	May attenuate metabolic & cardiovascular benefits of estrogen
Estrogen Alone	Indication	Hysterectomised women
	When used	Progestin not tolerated or contraindicated
	Dose rule	Use lowest dose that controls symptoms
	Preferred route	Transdermal estradiol (advantages)
Menopausal Symptoms	Vasomotor symptoms	Respond promptly and almost completely → primary indication for HRT
	Other benefits	Improves sleep, body aches, physical, mental & sexual wellbeing
	Mood	Estrogen improves depression; progestin may nullify benefit
	Stop rule	Discontinue HRT once vasomotor symptoms abate
Atrophic Changes	Genital & dermal	Arrested by estrogen
	Urogenital symptoms	Vulval & urinary problems resolve
	Vaginal estrogen	Effective for local symptoms & dyspareunia
	Preferred use	When local symptoms are the only aim
Osteoporosis	Effect	Restores Ca balance; prevents further bone loss; nullifies fracture risk
	Timing	Must start before significant bone loss
	Reversal	Reversal of osteoporosis is minimal or absent
	Adjuncts	Calcium, vitamin D, exercise
	After stopping	Accelerated bone loss restarts
	Dose effect	0.3–0.45 mg/day ↑ BMD; 0.625 mg/day more effective
	Current status	Estrogens removed as treatment for osteoporosis
	Preferred drugs	Bisphosphonates = drugs of choice
	Recommendation	HRT not best for prevention/treatment; not >5 yrs or >60 yrs
Cardiovascular Effects	Favorable mechanisms	↑ HDL:LDL ratio, ↓ atherogenesis, ↓ arterial impedance, ↑ NO & PGI₂, ↓ hyperinsulinemia
	Older women with CVD	3× ↑ VTE risk; ↑ MI risk in 1st year
	Secondary prevention	❌ No role in long-term CAD prophylaxis
	Progestin effect	↑ MI risk attributed mainly to progestin
	Estrogen alone	No increase in MI incidence
	Timing hypothesis	HRT within 10 yrs of menopause → ~30% ↓ MI
	Final CV rule	Short-term HRT soon after menopause (<60 yrs) may be protective
Cognition & Dementia	WHIMS findings	No cognitive protection
	Effect	Slight global deterioration
	Dementia	Alzheimer’s incidence doubled
Cancer – Breast	Effect	Estrogen enhances growth of existing breast cancer
	WHI study	Small replacement doses do not induce new cancer
	Combined HRT	Slightly higher risk (MPA implicated)
	Observational data	Estrogen alone → marginal ↑ risk; Estrogen + progestin → clear ↑ risk (MWS)
	Key balance	Endometrial protection by progestin offset by breast cancer risk
Cancer – Endometrium	Estrogen effect	Induces hyperplasia
	Unopposed estrogen	Irregular bleeding → long-term carcinoma risk
	Standard practice	Combined HRT if uterus intact
	Low-dose estrogen	No significant ↑ risk (Cochrane)
	Special use	Low-dose estrogen alone if progestin contraindicated
Cancer – Colorectal	Effect	Small protective effect (WHI)
	Status	Needs confirmation
Other Risks	Gallstones	Estrogen slightly ↑ risk
	Migraine	Progestins may trigger
Tibolone	Class	19-norsteroid
	Metabolites	Estrogenic, progestogenic, weak androgenic
	Dose	2.5 mg daily
	Effects	Suppresses menopausal symptoms; ↓ Gonadotrophins levels
	Endometrium	No stimulation
	Benefits	Improves urogenital atrophy, mood, libido, osteoporosis
	Contraindications	Same as conventional HRT
	Limitations	Long-term risks unclear
	Side effects	Weight gain, facial hair, spotting
	Use rule	Start only after ≥12 months menopause
	Preparation	UVIAL 2.5 mg — continuous daily
Senile Vaginitis	Preferred therapy	Topical estrogen
	Add-ons	Antibacterial if needed
	Benefits	Relieves vaginal infection & kraurosis vulvae
Delayed Puberty	Indication	Turner syndrome, hypopituitarism
	Regimen	Cyclic estrogen from 12–13 yrs → adult dose
	Later	Add cyclic progestin
	Height	GH ± low-dose androgen
	Duration	Continue till menopausal age (~50 yrs)
Dysmenorrhea	First line	PG synthesis inhibitors
	Hormonal role	Cyclic estrogen + progestin inhibits ovulation & PG synthesis
	Use	Reserved for severe cases
Acne	Cause	Increased androgen secretion
	Mechanism	Estrogen suppresses ovarian androgen via Gn inhibition
	Use	Cyclic estrogen + progestin effective in girls
	Limitation	❌ Not used in boys
	Preference	Topical therapy preferred
DUB	Treatment	Cyclic progestin = rational & effective
	Estrogen	Adjuvant role
Carcinoma Prostate	Role	Estrogens palliative
	Mechanism	Suppress androgen production via pituitary
	Current preference	GnRH agonists ± anti-androgens